Athersys Awarded $3.6 Million in Grant Funding For Stem Cell Product Development: http://t.co/bkQAMsRf
posted 2 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the FDA intended to grant its recently-submitted ocriplasmin BLA (Biological License Application) for Priority Review. The FDA grants Priority Review designation to drugs that may offer major advances in treatment, or provide a treatment where no adequate therapy exists. The FDA has a goal of completing a Priority Review in just six months. read more
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor® (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V. Terms of the agreement have not been disclosed. read more
BD (Becton, Dickinson and Company), een toonaangevend bedrijf in medische technologie dat wereldwijd actief is, heeft de lancering bekendgemaakt van een nieuwe I.V. veiligheidskatheter. De BD Insyte™ Autoguard™ BC met bloedcontroletechnologie vermindert het risico op blootstelling aan bloed met 95%. read more
FUGEIA NV kondigt vandaag aan dat het een samenwerkingsakkoord heeft afgesloten met NESTLE voor het ontwikkelen van voedingsmiddelen die Brana Vita[TM]bevatten. read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that three leading retinal specialists will present the responder analysis on ocriplasmin, a potentially novel treatment for retinal disorders, at the 2011 AAO Annual Meeting in Orlando, USA (21-25 October 2011). read more
